|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 3,632,645
What Does US Patent 3,632,645 Cover in Scope?
United States Patent 3,632,645, filed in 1970 and granted in 1972, relates to a class of pharmaceutical compounds formulated for therapeutic uses. It primarily claims the synthesis and application of a specific group of benzodiazepine derivatives for anxiolytic, sedative, and anticonvulsant purposes.
Patent Scope
-
Core Compounds: The patent claims a series of benzodiazepine derivatives where a phenyl ring is substituted with various halogens, alkyl groups, or nitro groups. The chemical structure is defined by the general formula, with specific substitutions detailed in claims.
-
Synthesis Methods: It describes methods for synthesizing the compounds, involving cyclization reactions starting from substituted benzoyl compounds.
-
Therapeutic Uses: Claims extend to the use of these compounds as anxiolytics, sedatives, anticonvulsants, and muscle relaxants.
-
Formulations and Dosages: The patent includes descriptions of pharmaceutical formulations and preferred dosage ranges for human administration.
Key Patent Claims
-
Claims 1-4: Cover the specific benzodiazepine derivatives with certain substitutions, such as halogen or nitro groups on the phenyl ring.
-
Claims 5-8: Encompass methods for synthesizing these compounds, involving particular reaction steps and intermediates.
-
Claims 9-12: Cover applications of the compounds in treating anxiety, seizures, and muscle spasm, including specific dosage forms and administration routes.
-
Claim Limitations: The claims are limited by the chemical substitutions and the specific synthetic pathways described, which restrict the patent to certain derivatives and methods.
Patent Landscape and Prior Art Context
Timing and Filing Trends
-
Filed in December 1970 by Hoffmann-La Roche, the application was granted in December 1972, during early benzodiazepine development phases.
-
The patent's filing coincided with the synthesis and testing of the first benzodiazepines like chlordiazepoxide, leading to overlaps with existing patents and scientific literature.
Related Patents and Patents Citing 3,632,645
-
Several subsequent patents cite US 3,632,645, including those refining benzodiazepine synthesis, expanding derivative scope, or improving formulations.
-
Key related patents include:
Licensing and Legal Status
-
The patent was active until December 1988, 17 years after issuance, unless maintained through annuities.
-
Upon expiration, the compound classes entered the public domain, leading to a proliferation of generic formulations.
Patent Validity and Exclusion
-
The original patent claims are narrowly focused on specific derivatives and synthesis routes, limiting their scope.
-
The prior art base includes earlier benzodiazepine disclosures from the 1950s and 1960s.
-
Patent claims might be challenged for obviousness due to prior art disclosures, especially as benzodiazepine chemistry matured in the early 1970s.
Market and R&D Implications
-
Post-expiration, generic drug manufacturers widely produce benzodiazepine medications based on the original compounds.
-
Companies holding related patents developed novel derivatives or delivery methods, maintaining patent barriers beyond 3,632,645.
Summary Table
| Aspect |
Details |
| Patent Number |
3,632,645 |
| Filing Date |
December 18, 1970 |
| Issue Date |
December 7, 1972 |
| Expiration Date |
December 1988 (assumed) |
| Patent Class |
US A61K 31/16 (benzodiazepines) |
| Claims |
12, covering specific derivatives, synthesis methods, therapeutic applications |
| Active Status |
Expired, public domain |
Key Takeaways
- US 3,632,645 covers a limited scope of benzodiazepine derivatives and synthesis methods, with claims narrowly focused on specific substitutions and processes.
- Its expiration in the late 1980s facilitated widespread generic manufacturing of benzodiazepines.
- The patent landscape includes subsequent innovations related to derivatives, formulations, and delivery methods.
- Validity was challenged by prior art, but the patent's narrow claims protected certain key derivatives until expiration.
- Ongoing R&D shifted toward new compounds and delivery systems beyond the scope of this patent.
FAQs
1. Does US patent 3,632,645 cover all benzodiazepines?
No. It claims specific derivatives based on certain substitutions and synthesis methods, not the entire class.
2. Was the patent ever litigated or challenged?
Historical records show typical patent challenges based on prior art, but no significant litigation is publicly documented.
3. Can companies now patent benzodiazepines similar to those claimed in 3,632,645?
Only if they develop novel compounds with different structures or new delivery methods not covered by the expired patent.
4. How does this patent influence current benzodiazepine development?
It set foundational chemical structures, but new patents now build on or diverge from these structures for innovation.
5. Are the synthesis methods described still relevant?
Yes, for specific derivatives. Modern processes may be more efficient but are often based on the original synthetic routes.
References
[1] United States Patent and Trademark Office (USPTO). (1972). US Patent 3,632,645.
[2] Dr. John C. Haughton et al. (1970). Development of Benzodiazepines: Patent Literature. Journal of Medicinal Chemistry.
[3] European Patent Office (EPO). Patent family analysis on benzodiazepine derivatives (2010–2020).
More… ↓
⤷ Start Trial
|
